| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d137f8e7503ba75f6edf7cbdf54e98c7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-07 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-06 |
| filingDate |
2012-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95dd31e2aa4544b3df5ab5e93668a732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53b51b4ece78e934698552f7e2d18af8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86d859d2bc944308436f86e2c16ee9d1 |
| publicationDate |
2014-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
MX-2014003509-A |
| titleOfInvention |
PROCESSES AND INTERMEDIARIES FOR THE PREPARATION OF A MACROCICLIC INHIBITOR OF THE PROTECTION OF THE VIRUS OF HEPATITIS C. |
| abstract |
A process for the preparation of a cinconidine salt of the formula (IV) is described (see Formula) by an aqueous solution of a 4-hydroxy-1,2-cyclopentandicarboxylic or racemic acid, which is cycled without removal of the water, by adding an organic solvent miscible with water to the aqueous solution and, once again without removing the water, add cinconidine to the aqueous solution of organic solvent in order to obtain the cinconidine salt of lactone acid; The cinconidine salt is allowed to crystallize to obtain the cinchonidine salt of the enantiomerically purified crystalline lactone acid (IV); The enantiomerically pure salt is an intermediate in the synthesis of the inhibitor of the HVC inhibitor compound of the formula (I). |
| priorityDate |
2011-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |